At the time of writing, Mersana Therapeutics Inc [MRSN] stock is trading at $4.06, up 7.12%. An important factor to consider is whether the stock is rising or falling in short-term value. The MRSN shares have gain 6.84% over the last week, with a monthly amount glided 28.08%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 21, February 2024, Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024. In a post published today on Yahoo Finance, Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, February 28, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
From an analyst’s perspective:
Mersana Therapeutics Inc [NASDAQ: MRSN] stock has seen the most recent analyst activity on December 04, 2023, when Citigroup upgraded its rating to a Buy and also boosted its price target to $5 from $1. Previously, Robert W. Baird downgraded its rating to Neutral on July 28, 2023, and dropped its price target to $1. On July 27, 2023, downgrade downgraded it’s rating to Neutral. Truist downgraded its rating to a Hold. JP Morgan downgraded its rating to a Underweight. Guggenheim downgraded its rating to Neutral for this stock on July 27, 2023. In a note dated July 27, 2023, Citigroup downgraded an Neutral rating on this stock.
For the past year, the stock price of Mersana Therapeutics Inc fluctuated between $0.80 and $9.62. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Mersana Therapeutics Inc [NASDAQ: MRSN] shares were valued at $4.06 at the most recent close of the market. An investor can expect a potential return of 367.98% based on the average MRSN price forecast.
Analyzing the MRSN fundamentals
According to Mersana Therapeutics Inc [NASDAQ:MRSN], the company’s sales were 40.84M for trailing twelve months, which represents an 38.13% jump. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.81 points at the first support level, and at 3.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.20, and for the 2nd resistance point, it is at 4.35.
Mersana Therapeutics Inc [MRSN] reported earnings per share of -$0.35 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.36/share, meaning a difference of $0.01 and a surprise factor of 2.80%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.47 per share as compared to estimates of -$0.44 per share, a difference of -$0.03 representing a surprise of -6.80%.
Ratios To Look Out For
It is important to note that Mersana Therapeutics Inc [NASDAQ:MRSN] has a current ratio of 3.68. On the other hand, the Quick Ratio is 3.68, and the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 11.99, the price to book ratio is 9.38.
Transactions by insiders
Recent insider trading involved Protopapas Anna, Director, that happened on Jan 16 when 29399.0 shares were sold. SVP, Chief Sci.&Tech. Officer, Lowinger Timothy B completed a deal on Jan 16 to sell 10409.0 shares. Meanwhile, SVP, COO & CFO DeSchuytner Brian sold 9327.0 shares on Jan 16.
